Literature DB >> 9753063

Establishment and characterization of a mantle cell lymphoma cell line.

H J Jeon1, C W Kim, T Yoshino, T Akagi.   

Abstract

A mantle cell lymphoma (MCL) cell line (JeKo-1) was established from peripheral blood mononuclear cells of a patient with a large cell variant of MCL showing leukaemic conversion. JeKo-1 cells were Epstein-Barr virus negative and showed a B-cell phenotype with IgM+, IgD+, CD3-, CD5+, CD10-, CD19+, CD20+ and CD23-; they overexpressed cyclin D1, Bcl-2, c-Myc and Rb proteins. Bcl-1/J(H) gene rearrangement was confirmed by polymerase chain reaction, although karyotypic analysis showed 40/41 chromosomes devoid of apparent t(11;14)(q13;q32) translocation. JeKo-1 cells were highly tumourigenic in SCID mice.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9753063     DOI： 10.1046/j.1365-2141.1998.00911.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  17 in total

1.  The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

Authors:  Viola Biberacher; Thomas Decker; Madlen Oelsner; Michaela Wagner; Christian Bogner; Burkhard Schmidt; Robert J Kreitman; Christian Peschel; Ira Pastan; Christian Meyer Zum Büschenfelde; Ingo Ringshausen
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes.

Authors:  Rajesh Mukthavaram; Guixin Shi; Santosh Kesari; Dmitri Simberg
Journal:  J Control Release       Date:  2014-03-28       Impact factor: 9.776

3.  UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells.

Authors:  Samantha A Swenson; Tyler J Gilbreath; Heather Vahle; R Willow Hynes-Smith; Jared H Graham; Henry C-H Law; Catalina Amador; Nicholas T Woods; Michael R Green; Shannon M Buckley
Journal:  Blood       Date:  2020-07-16       Impact factor: 22.113

4.  ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.

Authors:  Rajeswaran Mani; Chi-Ling Chiang; Frank W Frissora; Ribai Yan; Xiaokui Mo; Sivasubramanian Baskar; Christoph Rader; Rebecca Klisovic; Mitch A Phelps; Ching-Shih Chen; Robert J Lee; John C Byrd; Robert Baiocchi; L James Lee; Natarajan Muthusamy
Journal:  Exp Hematol       Date:  2015-04-29       Impact factor: 3.084

5.  Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.

Authors:  Yoko Tabe; Linhua Jin; Marina Konopleva; Masato Shikami; Shinya Kimura; Michael Andreeff; Mark Raffeld; Takashi Miida
Journal:  Acta Haematol       Date:  2013-09-19       Impact factor: 2.195

6.  Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease.

Authors:  Lan V Pham; Muychi T Vang; Archito T Tamayo; Gary Lu; Pramoda Challagundla; Jeffrey L Jorgensen; Alex A Rollo; Zhishuo Ou; Liang Zhang; Michael Wang; Richard J Ford
Journal:  Leuk Lymphoma       Date:  2014-04-29

7.  Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

Authors:  Lapo Alinari; Bo Yu; Beth A Christian; Fengting Yan; Jungook Shin; Rosa Lapalombella; Erin Hertlein; Mark E Lustberg; Carl Quinion; Xiaoli Zhang; Gerard Lozanski; Natarajan Muthusamy; Mette Prætorius-Ibba; Owen A O'Connor; David M Goldenberg; John C Byrd; Kristie A Blum; Robert A Baiocchi
Journal:  Blood       Date:  2011-01-12       Impact factor: 22.113

8.  FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.

Authors:  Lapo Alinari; Emilia Mahoney; John Patton; Xiaoli Zhang; Lenguyen Huynh; Christian T Earl; Rajeswaran Mani; Yicheng Mao; Bo Yu; Carl Quinion; William H Towns; Ching-Shih Chen; David M Goldenberg; Kristie A Blum; John C Byrd; Natarajan Muthusamy; Mette Praetorius-Ibba; Robert A Baiocchi
Journal:  Blood       Date:  2011-10-31       Impact factor: 22.113

9.  The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.

Authors:  David M Lucas; Lapo Alinari; Derek A West; Melanie E Davis; Ryan B Edwards; Amy J Johnson; Kristie A Blum; Craig C Hofmeister; Michael A Freitas; Mark R Parthun; Dasheng Wang; Amy Lehman; Xiaoli Zhang; David Jarjoura; Samuel K Kulp; Carlo M Croce; Michael R Grever; Ching-Shih Chen; Robert A Baiocchi; John C Byrd
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

10.  Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression.

Authors:  Christian Bogner; Tobias Dechow; Ingo Ringshausen; Michaela Wagner; Madlen Oelsner; Gloria Lutzny; Thomas Licht; Christian Peschel; Ira Pastan; Robert J Kreitman; Thomas Decker
Journal:  Br J Haematol       Date:  2009-10-11       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.